VolitionRX/VNRX

$1.01

-2.88%
-
1D1W1MYTD1YMAX

About VolitionRX

VolitionRx Limited is a multi-national epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop blood tests to help diagnose and monitor a range of diseases, including certain cancers and diseases associated with NETosis, such as sepsis and COVID-19. The Company’s tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluids. Its Nucleosomics technology uses chromosomal structures called nucleosomes as biomarkers in cancer and other diseases. Its key pillars include Nu.Q Cancer , Nu.Q NETs, Nu.Q Capture, Nu.Q Discover and Nu.Q Vet. Its Nu.Q family of tests acts as an early warning system by monitoring treatment response, disease progression and remission. Its Nu.Q tests use epigenetic information from tumor cells nucleosomes that helps physicians select the treatment for each patient, monitor their response and disease progression.

Ticker

VNRX

Sector

Healthcare

Trading on

AMEX

Industry

Biotechnology & Drugs

CEO

Cameron Reynolds

Employees

104

Headquarters

Henderson, United States

VolitionRX Metrics

BasicAdvanced
$81.83M
Market cap
-
P/E ratio
-$0.52
EPS
1.38
Beta
-
Dividend rate

What the Analysts think about VolitionRX

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 3 analysts.
263.37% upside
High $4.50
Low $2.50
$1.01
Current price
$3.67
Average price target

VolitionRX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-8,300% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$100K
-50%
Net income
$-8.3M
-11.7%
Profit margin
-8,300%
76.6%

VolitionRX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 15.38%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.13
-$0.15
-$0.14
-$0.11
-
Expected
-$0.15
-$0.14
-$0.15
-$0.13
-$0.11
Surprise
-10.96%
7.14%
-5.08%
-15.38%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell VolitionRX stock

Buy or sell VolitionRX stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing